Physician

Narender Rao Jogenpally, MD

According to 2025 Medicare claims, Narender Jogenpally, MD (NPI: 1396741880) practices hematology/oncology in the Charleston, WV market, with the plurality of this provider's patient population coming from Kanawha, WV. This provider's primary affiliated billing organization is THS PHYSICIAN PARTNERS INC (NPI: 1871866806; TIN: 45-4395947) and primary practice location at 25309-1311. Jogenpally is affiliated with the ACO West Virginia (ACO ID: A3563), participating under the MSSP model.

Jogenpally's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 614 traditional Medicare patients, billed 2,019 HCPCS/CPT codes, and received $133,762 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 2,414 prescription claims across 368 beneficiaries totaling $7,137,606 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 36 claims. Open Payments data shows 1 records totaling $111. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $570,335 to $7,137,606. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,064 and ending at $2,438.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	683	17,582	$250,844
2016	823	2,480	$140,789
2017	738	2,367	$128,183
2018	695	2,193	$121,195
2019	659	2,050	$113,668
2020	588	1,881	$110,566
2021	588	1,746	$114,038
2022	589	1,783	$110,509
2023	616	2,031	$130,729
2024	614	2,019	$133,762

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	192	1,007	$570,335
2016	261	1,843	$2,125,014
2017	276	2,038	$2,944,312
2018	295	2,150	$3,403,585
2019	290	1,968	$3,206,178
2020	284	2,126	$3,903,870
2021	276	1,748	$3,729,885
2022	283	1,580	$3,125,653
2023	325	1,858	$4,541,244
2024	368	2,414	$7,137,606

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	95	$4,299
2016	N/R	136	$5,638
2017	N/R	220	$7,206
2018	N/R	133	$7,618
2019	N/R	59	$3,107
2020	N/R	64	$6,735
2021	N/R	67	$6,784
2022	N/R	105	$7,918
2023	N/R	36	$992
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	88	101	$101
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	67	67	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	367	714	$69
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	159	656	$61
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	210	261	$47

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	69	1,932	$1,085,053
Tasigna	Nilotinib Hcl	40	1,122	$706,464
Jakafi	Ruxolitinib Phosphate	37	1,110	$623,126
Pomalyst	Pomalidomide	29	693	$545,263
Lenalidomide	Lenalidomide	43	1,043	$491,160

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$111	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Narender Rao Jogenpally, MD?

Tedicare shows public-source Medicare data for Narender Rao Jogenpally, MD (NPI 1396741880), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Narender Rao Jogenpally, MD have ACO affiliation data?

Narender Rao Jogenpally, MD is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563).

What billing organization is linked to Narender Rao Jogenpally, MD?

Narender Rao Jogenpally, MD is linked to THS PHYSICIAN PARTNERS INC (billing NPI 1871866806) in the available physician profile data.

Does Narender Rao Jogenpally, MD have Open Payments data?

Narender Rao Jogenpally, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.